News
Follow us for the latest news

JHM Biopharmaceutical Completes Nearly CN¥200 Million Series C Financing

JHM Biopharmaceutical (Hangzhou) Co., Ltd. (“JHM …

Learn More

JHM Biopharmaceutical has initiated the Phase III trial for recombinant botulinum neurotoxin of type A in treating upper limb spasticity in adults, with enrollment of the first patient completed.

Today, JHM Biopharmaceutical (Hangzhou) Co., Ltd. (here…

Learn More

JHM Biopharmaceutical Begins Clinical Trial of its Recombinant Type A Botulinum Toxin for Stroke-Related Spasticity

JHM Biopharmaceutical (Hangzhou) Co., Ltd. (“JHM&…

Learn More

JHM Biopharmaceutical Raises Nearly CN¥350 million in Series B and B+ Financing

JHM Biopharmaceutical (Hangzhou) Co., Ltd. (“JHM&…

Learn More

JHM Biopharmaceutical Receives Approval for Clinical Trial of its Recombinant Type A Botulinum Toxin for Stroke Spasticity

JHM Biopharmaceutical (Hangzhou) Co., Ltd. (“JHM&…

Learn More